Lincoln Pharmaceuticals Limited manufactures and sells pharmaceutical products in India and internationally. More Details
Flawless balance sheet and undervalued.
Share Price & News
How has Lincoln Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LINCOLN is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: LINCOLN's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: LINCOLN exceeded the Indian Pharmaceuticals industry which returned 42.2% over the past year.
Return vs Market: LINCOLN underperformed the Indian Market which returned 74.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Lincoln Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?
1 month ago | Simply Wall StDoes Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?
Is Lincoln Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LINCOLN (₹237.75) is trading below our estimate of fair value (₹690.45)
Significantly Below Fair Value: LINCOLN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LINCOLN is good value based on its PE Ratio (7.9x) compared to the IN Pharmaceuticals industry average (19.3x).
PE vs Market: LINCOLN is good value based on its PE Ratio (7.9x) compared to the Indian market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LINCOLN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LINCOLN is good value based on its PB Ratio (1.3x) compared to the IN Pharmaceuticals industry average (2.3x).
How is Lincoln Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lincoln Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Lincoln Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LINCOLN has high quality earnings.
Growing Profit Margin: LINCOLN's current net profit margins (13.9%) are higher than last year (13.2%).
Past Earnings Growth Analysis
Earnings Trend: LINCOLN's earnings have grown by 19.5% per year over the past 5 years.
Accelerating Growth: LINCOLN's earnings growth over the past year (14.9%) is below its 5-year average (19.5% per year).
Earnings vs Industry: LINCOLN earnings growth over the past year (14.9%) underperformed the Pharmaceuticals industry 39.9%.
Return on Equity
High ROE: LINCOLN's Return on Equity (16.8%) is considered low.
How is Lincoln Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LINCOLN's short term assets (₹3.1B) exceed its short term liabilities (₹883.7M).
Long Term Liabilities: LINCOLN's short term assets (₹3.1B) exceed its long term liabilities (₹101.3M).
Debt to Equity History and Analysis
Debt Level: LINCOLN's debt to equity ratio (5.2%) is considered satisfactory.
Reducing Debt: LINCOLN's debt to equity ratio has reduced from 47.6% to 5.2% over the past 5 years.
Debt Coverage: LINCOLN's debt is well covered by operating cash flow (490.3%).
Interest Coverage: LINCOLN earns more interest than it pays, so coverage of interest payments is not a concern.
What is Lincoln Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: LINCOLN's dividend (0.65%) is higher than the bottom 25% of dividend payers in the Indian market (0.43%).
High Dividend: LINCOLN's dividend (0.65%) is low compared to the top 25% of dividend payers in the Indian market (1.9%).
Stability and Growth of Payments
Stable Dividend: LINCOLN's dividend payments have been volatile in the past 10 years.
Growing Dividend: LINCOLN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (5.1%), LINCOLN's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mahendrabhai Patel (66 yo)
Mr. Mahendrabhai Gulabdas Patel, B.A, LLB serves as Managing Director of Lincoln Pharmaceuticals Ltd. Mr. Patel has varied experience of chemicals, steel, finance etc. Mr. Patel handles corporate planning ...
CEO Compensation Analysis
Compensation vs Market: Mahendrabhai's total compensation ($USD30.85K) is about average for companies of similar size in the Indian market ($USD41.03K).
Compensation vs Earnings: Mahendrabhai's compensation has increased by more than 20% in the past year.
Experienced Management: LINCOLN's management team is considered experienced (2.8 years average tenure).
Experienced Board: LINCOLN's board of directors are seasoned and experienced ( 23.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LINCOLN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lincoln Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: Lincoln Pharmaceuticals Limited
- Ticker: LINCOLN
- Exchange: NSEI
- Founded: 1979
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹4.636b
- Shares outstanding: 20.00m
- Website: https://www.lincolnpharma.com
Number of Employees
- Lincoln Pharmaceuticals Limited
- Lincoln House
- Behind Satyam Complex
Lincoln Pharmaceuticals Limited manufactures and sells pharmaceutical products in India and internationally. It offers products in the areas of anti-infective, respiratory system, gynecology, cardio and CN...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/16 12:09|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.